» Articles » PMID: 22654675

EMT Inducers Catalyze Malignant Transformation of Mammary Epithelial Cells and Drive Tumorigenesis Towards Claudin-low Tumors in Transgenic Mice

Abstract

The epithelial-mesenchymal transition (EMT) is an embryonic transdifferentiation process consisting of conversion of polarized epithelial cells to motile mesenchymal ones. EMT-inducing transcription factors are aberrantly expressed in multiple tumor types and are known to favor the metastatic dissemination process. Supporting oncogenic activity within primary lesions, the TWIST and ZEB proteins can prevent cells from undergoing oncogene-induced senescence and apoptosis by abolishing both p53- and RB-dependent pathways. Here we show that they also downregulate PP2A phosphatase activity and efficiently cooperate with an oncogenic version of H-RAS in malignant transformation of human mammary epithelial cells. Thus, by down-regulating crucial tumor suppressor functions, EMT inducers make cells particularly prone to malignant conversion. Importantly, by analyzing transformed cells generated in vitro and by characterizing novel transgenic mouse models, we further demonstrate that cooperation between an EMT inducer and an active form of RAS is sufficient to trigger transformation of mammary epithelial cells into malignant cells exhibiting all the characteristic features of claudin-low tumors, including low expression of tight and adherens junction genes, EMT traits, and stem cell-like characteristics. Claudin-low tumors are believed to be the most primitive breast malignancies, having arisen through transformation of an early epithelial precursor with inherent stemness properties and metaplastic features. Challenging this prevailing view, we propose that these aggressive tumors arise from cells committed to luminal differentiation, through a process driven by EMT inducers and combining malignant transformation and transdifferentiation.

Citing Articles

EMT-driven plasticity prospectively increases cell-cell variability to promote therapeutic adaptation in breast cancer.

Muller L, Fauvet F, Chassot C, Angileri F, Coutant A, Degletagne C Cancer Cell Int. 2025; 25(1):32.

PMID: 39901189 PMC: 11789407. DOI: 10.1186/s12935-025-03637-w.


Specific modulation of 28S_Um2402 rRNA 2'--ribose methylation as a novel epitranscriptomic marker of ZEB1-induced epithelial-mesenchymal transition in different mammary cell contexts.

Morin C, Paraqindes H, Nguyen Van Long F, Isaac C, Thomas E, Pedri D NAR Cancer. 2025; 7(1):zcaf001.

PMID: 39877292 PMC: 11773364. DOI: 10.1093/narcan/zcaf001.


Intricate ribosome composition and translational reprogramming in epithelial-mesenchymal transition.

Morin C, Baudin-Baillieu A, Nguyen Van Long F, Isaac C, Bidou L, Arbes H Proc Natl Acad Sci U S A. 2024; 121(50):e2408114121.

PMID: 39636864 PMC: 11648652. DOI: 10.1073/pnas.2408114121.


The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.

Masciale V, Banchelli F, Grisendi G, Samarelli A, Raineri G, Rossi T J Biol Chem. 2024; 300(12):107994.

PMID: 39547513 PMC: 11714729. DOI: 10.1016/j.jbc.2024.107994.


Elevated GRHL2 Imparts Plasticity in ER-Positive Breast Cancer Cells.

Zheng C, Allen K, Liu T, Solodin N, Meyer M, Salem K Cancers (Basel). 2024; 16(16).

PMID: 39199676 PMC: 11353109. DOI: 10.3390/cancers16162906.


References
1.
Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

2.
Acloque H, Adams M, Fishwick K, Bronner-Fraser M, Nieto M . Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009; 119(6):1438-49. PMC: 2689100. DOI: 10.1172/JCI38019. View

3.
Husemann Y, Geigl J, Schubert F, Musiani P, Meyer M, Burghart E . Systemic spread is an early step in breast cancer. Cancer Cell. 2008; 13(1):58-68. DOI: 10.1016/j.ccr.2007.12.003. View

4.
Pallas D, Shahrik L, Martin B, Jaspers S, Miller T, Brautigan D . Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell. 1990; 60(1):167-76. DOI: 10.1016/0092-8674(90)90726-u. View

5.
Hoeflich K, OBrien C, Boyd Z, Cavet G, Guerrero S, Jung K . In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009; 15(14):4649-64. DOI: 10.1158/1078-0432.CCR-09-0317. View